Opinion

Video

Clinical Data on Finerenone in Diabetic Kidney Disease

Author(s):

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Related Content
FDA logo in black over a white background. | Credit: US Food and Drug Administration
December 20th 2024

FDA Issues CRL for Sotagliflozin in Type 1 Diabetes and CKD

Patrick Campbell
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia | Image Credit: US Food and Drug Administration
Published: December 13th 2024 | Updated: December 13th 2024

FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia

Connor Iapoce
Mifepristone Significantly Reduces HbA1c in Treatment Phase of CATALYST | Image Credit: LinkedIn
December 12th 2024

Mifepristone Notably Reduces HbA1c in Treatment Phase of CATALYST Trial

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.